May 17, 2020

Pristine or OrCam: are Google Glasses a telemedicine solution or a resource for visually impaired patients?

2 min
Pristine or OrCam are Google Glasses a telemedicine solution or a resource for visually impaired patients.jpg
Google Glasses have already revolutionized the healthcare industry from its work in medical universities training future doctors, providing research op...

Google Glasses have already revolutionized the healthcare industry from its work in medical universities training future doctors, providing research opportunities for practicing physicians, real-time surgical benefits and giving resources to visually impaired individuals. As a leader now in wearable technology, two companies have pioneered this technology to the next level as the competition on who best uses this technology continues to grow.

Pristine and OrCam have incorporated cameras into the Google Glass technology, taking it further than any other company has yet to. Whereas Pristine uses the camera technology to incorporate additional physicians on telemedicine consultations, OrCAm also uses the camera to see more clearly what its visually impaired user cannot. Both of these usages reflect a unique target market and development strategy, what both also come at a steep price.

Coming in at nearly $2,500 a piece, Israel-based OrCAm’s adapted Google Glasses interpret visual images the wearer points to and through a speaker by their ear, hears what they are looking at whether it’s a train number, or text in their favorite book. Due to its expensive price tag not all patients will be able to afford this technology; however, the company is currently in negotiations of how to change its non-reimbursed status. The WHO estimates that 285 million people today are visually impaired, and this presents not only a profitable market for their technology, but an opportunity to help a lot of people in need.

Pristine comes in at the other end of the spectrum, focusing on the Glasses telemedicine capabilities. Though early on in its development, Pristine is piloting its EyeSight application in their unique approach to telemedicine in a more flexible approach than what is currently being used in teleconsultaitons today. Partnering with Wound Care Advantage, Pristine has signaled interest into expanding into the telewound market as well. Not only will Pristine’s technology increase access to care, but it will make telemedicine more efficient and has the potential to help a greater number of people.

So between these two Google-glass developers, who stands on top of their respective emerging market?

Share article

Jun 18, 2021

Skin Analytics wins NHSX award for AI skin cancer tool 

2 min
Skin Analytics uses AI to detect skin cancer and will be deployed across the NHS to ease patient backlogs

An artificial intelligence-driven tool that identifies skin cancers has received an award from NHSX, the NHS England and Department of Health and Social Care's initiative to bring technology into the UK's national health system. 

NHSX has granted the Artificial Intelligence in Health and Care Award to DERM, an AI solution that can identify 11 types of skin lesion. 

Developed by Skin Analytics, DERM analyses images of skin lesions using algorithms. Within primary care, Skin Analytics will be used as an additional tool to help doctors with their decision making. 

In secondary care, it enables AI telehealth hubs to support dermatologists with triage, directing patients to the right next step. This will help speed up diagnosis, and patients with benign skin lesions can be identified earlier, redirecting them away from dermatology departments that are at full capacity due to the COVID-19 backlog. 

Cancer Research has called the impact of the pandemic on cancer services "devastating", with a 42% drop in the number of people starting cancer treatment after screening. 

DERM is already in use at University Hospitals Birmingham and Mid and South Essex Health & Care Partnership, where it has led to a significant reduction in unnecessary referrals to hospital.

Now NHSX have granted it the Phase 4 AI in Health and Care Award, making DERM available to clinicians across the country. Overall this award makes £140 million available over four years to accelerate the use of artificial intelligence technologies which meet the aims of the NHS Long Term Plan.

Dr Lucy Thomas, Consultant Dermatologist at Chelsea & Westminster Hospital, said: “Skin Analytics’ receipt of this award is great news for the NHS and dermatology departments. It will allow us to gather real-world data to demonstrate the benefits of AI on patient pathways and workforce challenges. 

"Like many services, dermatology has severe backlogs due to the COVID-19 pandemic. This award couldn't have come at a better time to aid recovery and give us more time with the patients most in need of our help.”

Share article